阿托伐他汀对介入术后的冠心病慢性心力衰竭患者预后的影响分析

Atorvastatin after Interventional Treatment of Coronary Heart Disease in Patients with Chronic Heart Failure Prognosis

目的研究阿托伐他汀对介入术后的冠心病慢性心力衰竭患者预后的影响。方法选取我院在2008年3月至2011年11月收治的79例介入术后冠心病慢性心力衰竭患者,按照住院号尾号的奇偶将其分为研究组(39例)和观察组(40例)。两组患者均采用常规综合方法进行治疗,研究组患者在此基础上加用阿托伐他汀,每天两次,每次10mg。两组患者均在治疗前与治疗后进行C反应蛋白(CRP)、心室射血分数(LVEF)以及血脂全套,同时观察记录患者住院情况。结果而两组患者治疗后血脂情况对比具有差异性,有统计学意义(P<0.05);研究组患者治疗后WBC计数、hsCRP以及LVEF均优于观察组,有统计学意义(P<0.05);研究组患者平均住院时间短于观察组,病死率低于观察组,两组患者对比有统计学意义(P<0.05)。结论在常规治疗的基础上应用阿托伐他汀治疗介入术后的冠心病慢性心力衰竭患者,不仅可以提高治疗效果,还能够改善预后情况。

Objective To study atorvastatin after interventional treatment of coronary heart disease in patients with chronic heart failure prognosis. Methods The selected hospital in March 2008 to November 2011 were 79 cases after interventional treatment of coronary heart disease in patients with chronic heart failure, according to the parity number, hospital number to be divided into study group （39 cases） and the observation group （40 cases）. Patients in both groups using conventional integrated approach to treatment, the study group patients based on the addition of atorvastatin twice daily 10mg. C-reactive protein （CRP）, patients in both groups before treatment and after treatment, ventricular ejection fraction （LVEF） and blood lipids full set while observing the hospitalization of the patients were recorded. Results After treatment, lipids comparison with the differences statistically significant （P 〈0.05）; studied the treatment of patients, the WBC count, levels of hsCRP and LVEF are better than the observation group, with statistical significance （P 〈0.05 The）; study group of patients the average length of stay is shorter than the observation group, the fatality rate is lower than the observation group, the two groups were compared statistically significant （P〈0.05）. Conclusion The conventional treatment on the basis of Atto attacked him with statin therapy after interventional treatment of coronary heart disease in patients with chronic heart failure, not only can improve the therapeutic effect, but also to improve the prognosis.